News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,654 Results
Type
Article (41057)
Company Profile (265)
Press Release (683321)
Multimedia
Podcasts (82)
Webinars (18)
Section
Business (204717)
Career Advice (2026)
Deals (35540)
Drug Delivery (118)
Drug Development (81422)
Employer Resources (173)
FDA (16449)
Job Trends (14955)
News (346527)
Policy (32744)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2576)
Accelerated approval (38)
Adcomms (25)
Allergies (155)
Alliances (49577)
ALS (183)
Alzheimer's disease (1704)
Antibody-drug conjugate (ADC) (341)
Approvals (16733)
Artificial intelligence (560)
Autoimmune disease (198)
Automation (46)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (195)
Biotechnology (174)
Bladder cancer (171)
Brain cancer (61)
Breast cancer (670)
Cancer (5102)
Cardiovascular disease (428)
Career advice (1714)
Career pathing (38)
CAR-T (291)
CDC (50)
Celiac Disease (2)
Cell therapy (778)
Cervical cancer (40)
Clinical research (69958)
Collaboration (1807)
Company closure (4)
Compensation (1231)
Complete response letters (68)
COVID-19 (2721)
CRISPR (98)
C-suite (926)
Cystic fibrosis (145)
Data (6694)
Decentralized trials (2)
Denatured (25)
Depression (148)
Diabetes (532)
Diagnostics (6784)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (271)
Drug pricing (189)
Drug shortages (28)
Duchenne muscular dystrophy (261)
Earnings (90756)
Editorial (59)
Employer branding (21)
Employer resources (152)
Events (118002)
Executive appointments (1010)
FDA (19736)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (26)
Funding (1545)
Gene editing (209)
Generative AI (46)
Gene therapy (637)
GLP-1 (993)
Government (4683)
Grass and pollen (6)
Guidances (389)
Healthcare (18903)
HIV (69)
Huntington's disease (51)
IgA nephropathy (87)
Immunology and inflammation (259)
Immuno-oncology (71)
Indications (144)
Infectious disease (3020)
Inflammatory bowel disease (198)
Inflation Reduction Act (14)
Influenza (124)
Intellectual property (265)
Interviews (316)
IPO (16648)
IRA (50)
Job creations (3644)
Job search strategy (1429)
JPM (58)
Kidney cancer (18)
Labor market (90)
Layoffs (550)
Leadership (33)
Legal (7951)
Liver cancer (94)
Longevity (24)
Lung cancer (679)
Lymphoma (391)
Machine learning (47)
Management (59)
Manufacturing (870)
MASH (173)
Medical device (13822)
Medtech (13892)
Mergers & acquisitions (20014)
Metabolic disorders (1353)
mRNA (167)
Multiple sclerosis (171)
NASH (17)
Neurodegenerative disease (354)
Neuropsychiatric disorders (92)
Neuroscience (3034)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4522)
Now hiring (71)
Obesity (635)
Opinion (270)
Ovarian cancer (173)
Pain (216)
Pancreatic cancer (244)
Parkinson's disease (315)
Partnered (33)
Patents (535)
Patient recruitment (550)
Peanut (60)
People (59099)
Pharmaceutical (60)
Pharmacy benefit managers (30)
Phase 1 (21799)
Phase 2 (30793)
Phase 3 (22944)
Pipeline (6383)
Policy (300)
Postmarket research (2564)
Preclinical (9240)
Press Release (64)
Prostate cancer (265)
Psychedelics (49)
Radiopharmaceuticals (292)
Rare diseases (939)
Real estate (5957)
Recruiting (70)
Regulatory (24778)
Reports (53)
Research institute (2399)
Resumes & cover letters (353)
Rett syndrome (31)
RNA editing (16)
RSV (82)
Schizophrenia (153)
Series A (258)
Series B (194)
Service/supplier (11)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3620)
State (2)
Stomach cancer (18)
Supply chain (113)
Tariffs (84)
The Weekly (55)
Vaccines (1029)
Venture capital (92)
Weight loss (402)
Women's health (104)
Worklife (19)
Date
Today (115)
Last 7 days (505)
Last 30 days (2954)
Last 365 days (29962)
2026 (6371)
2025 (30172)
2024 (35213)
2023 (40075)
2022 (51174)
2021 (55711)
2020 (54085)
2019 (46539)
2018 (35018)
2017 (32110)
2016 (31481)
2015 (37552)
2014 (31321)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (737)
Alabama (86)
Alaska (7)
Arizona (321)
Arkansas (13)
Asia (39345)
Australia (6438)
California (11910)
Canada (3430)
China (1158)
Colorado (502)
Connecticut (511)
Delaware (353)
Europe (84959)
Florida (1801)
Georgia (377)
Hawaii (3)
Idaho (61)
Illinois (919)
India (74)
Indiana (546)
Iowa (22)
Japan (461)
Kansas (127)
Kentucky (43)
Louisiana (34)
Maine (73)
Maryland (1452)
Massachusetts (8543)
Michigan (338)
Minnesota (652)
Mississippi (6)
Missouri (134)
Montana (33)
Nebraska (29)
Nevada (131)
New Hampshire (81)
New Jersey (3167)
New Mexico (28)
New York (3130)
North Carolina (1521)
North Dakota (8)
Northern California (5867)
Ohio (354)
Oklahoma (21)
Oregon (41)
Pennsylvania (2402)
Puerto Rico (24)
Rhode Island (50)
South America (1111)
South Carolina (72)
South Dakota (1)
Southern California (4663)
Tennessee (193)
Texas (1848)
United States (42199)
Utah (358)
Vermont (1)
Virginia (280)
Washington D.C. (80)
Washington State (955)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
724,654 Results for "cytokinetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
·
5 min read
·
Dan Samorodnitsky
Press Releases
Cytokinetics to Participate in March 2026 Investor Conferences
March 3, 2026
·
3 min read
Press Releases
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
March 16, 2026
·
15 min read
Press Releases
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
February 12, 2026
·
3 min read
Press Releases
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
February 25, 2026
·
17 min read
Press Releases
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
February 17, 2026
·
9 min read
Cardiovascular disease
Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study
Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.
September 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
3 min read
Press Releases
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 20, 2026
January 21, 2026
·
4 min read
Press Releases
Cytokinetics to Participate in November 2025 Investor Conferences
November 4, 2025
·
3 min read
1 of 72,466
Next
